Randomized, Placebo-Controlled Trials of Antidepressants for Acute Major Depression: Thirty-Year Meta-Analytic Review

[1]  S. Melton.  Why antidepressants are not antidepressants , 2012 .

[2]  R. Baldessarini,et al.  Multisite international collaborative clinical trials in mania. , 2011, The international journal of neuropsychopharmacology.

[3]  M. Tohen,et al.  Factors modifying drug and placebo responses in randomized trials for bipolar mania. , 2011, The international journal of neuropsychopharmacology.

[4]  N. Khin,et al.  Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. , 2011, The Journal of clinical psychiatry.

[5]  J. Modell,et al.  Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR , 2010, Journal of psychopharmacology.

[6]  R. Baldessarini,et al.  Illness risk following rapid versus gradual discontinuation of antidepressants. , 2010, The American journal of psychiatry.

[7]  A. Leventhal,et al.  Efficacy and Effectiveness of Antidepressants: Current Status of Research , 2010, Psychotherapy and Psychosomatics.

[8]  P. Brovedani,et al.  Pharmacotherapy of major depressive disorder in adolescents , 2010, Expert opinion on pharmacotherapy.

[9]  J. Goethe,et al.  Last‐Observation‐Carried‐Forward Imputation Method in Clinical Efficacy Trials: Review of 352 Antidepressant Studies , 2009, Pharmacotherapy.

[10]  S. Montgomery,et al.  Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. , 2009, The Journal of clinical psychiatry.

[11]  M. Thase,et al.  Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features , 2009, International clinical psychopharmacology.

[12]  S. K. Padmanabhan,et al.  A Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible-Dose Desvenlafaxine Treatment in Outpatients with Major Depressive Disorder , 2009, CNS Spectrums.

[13]  S. Ghaemi.  Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression. , 2008, Bipolar disorders.

[14]  K. Lohr,et al.  Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians , 2008, Annals of Internal Medicine.

[15]  S. Montgomery,et al.  Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial , 2008, International clinical psychopharmacology.

[16]  S. Montgomery,et al.  A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder , 2008, International clinical psychopharmacology.

[17]  M. Liebowitz,et al.  Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder* , 2008 .

[18]  R. Baldessarini,et al.  Efficacy of antidepressants in juvenile depression: meta-analysis , 2008, British Journal of Psychiatry.

[19]  Blair T. Johnson,et al.  Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration , 2008, PLoS medicine.

[20]  R. Rosenthal,et al.  Selective publication of antidepressant trials and its influence on apparent efficacy. , 2008, The New England journal of medicine.

[21]  R. Shelton,et al.  Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents , 2007, Biological Psychiatry.

[22]  M. Liebowitz,et al.  A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. , 2007, The Journal of clinical psychiatry.

[23]  B. Pitrosky,et al.  A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder , 2007, International clinical psychopharmacology.

[24]  T. Furukawa,et al.  Metareview on Short-Term Effectiveness and Safety of Antidepressants for Depression: An Evidence-Based Approach to Inform Clinical Practice , 2007, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[25]  N. DeMartinis,et al.  A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. , 2007, The Journal of clinical psychiatry.

[26]  M. Thase,et al.  A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. , 2007, Journal of psychiatric research.

[27]  A. Nierenberg,et al.  Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study* , 2007, Current medical research and opinion.

[28]  K. Rickels,et al.  Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. , 2006, The Journal of clinical psychiatry.

[29]  M. Detke,et al.  Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial , 2006, European Psychiatry.

[30]  A. Rush,et al.  Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. , 2006, The Journal of clinical psychiatry.

[31]  N. Richard,et al.  Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. , 2006, The Journal of clinical psychiatry.

[32]  M. Gastpar,et al.  Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. , 2006, Pharmacopsychiatry.

[33]  R. Moreno,et al.  Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample. , 2006, Revista brasileira de psiquiatria.

[34]  M. Fava,et al.  A Double-blind, Randomized Trial of St John's Wort, Fluoxetine, and Placebo in Major Depressive Disorder , 2005, Journal of clinical psychopharmacology.

[35]  G. Edman,et al.  Hypericum extract LI 160 and fluoxetine in mild to moderate depression , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[36]  M. Detke,et al.  Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial , 2004, European Neuropsychopharmacology.

[37]  M. Trivedi,et al.  Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. , 2004, The Journal of clinical psychiatry.

[38]  U. Lepola,et al.  Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. , 2003 .

[39]  J. Amsterdam.  A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. , 2003, The Journal of clinical psychiatry.

[40]  M. Detke,et al.  Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. , 2002, Journal of psychiatric research.

[41]  J. Amsterdam,et al.  Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. , 2002, The American journal of psychiatry.

[42]  J. Rybakowski,et al.  Reboxetine, a New Noradrenaline Selective Antidepressant, Is at Least as Effective as Fluoxetine in the Treatment of Depression , 2002, Journal of clinical psychopharmacology.

[43]  C. Nemeroff,et al.  Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. , 2002, The Journal of clinical psychiatry.

[44]  M. Detke,et al.  Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine , 2002, European Neuropsychopharmacology.

[45]  R. Sysko,et al.  Placebo response in studies of major depression: variable, substantial, and growing. , 2002, JAMA.

[46]  Norma Pugh,et al.  Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. , 2002, JAMA.

[47]  W. Burke,et al.  Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. , 2002, The Journal of clinical psychiatry.

[48]  M. Detke,et al.  Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. , 2002, The Journal of clinical psychiatry.

[49]  M. Demitrack,et al.  Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. , 2002, The Journal of clinical psychiatry.

[50]  N. Richard,et al.  A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. , 2001, Clinical therapeutics.

[51]  I. Anderson,et al.  Meta-analytical studies on new antidepressants. , 2001, British medical bulletin.

[52]  S. Stahl.  Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline , 2000, Biological Psychiatry.

[53]  J. Feighner,et al.  Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. , 1999, The Journal of clinical psychiatry.

[54]  R. Kohnen,et al.  Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. , 1999, BMJ.

[55]  A. Feiger,et al.  A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. , 1999, Journal of affective disorders.

[56]  R. Donahue,et al.  Sexual Dysfunction Associated with the Treatment of Depression: A Placebo-Controlled Comparison of Bupropion Sustained Release and Sertraline Treatment , 1999, European Neuropsychopharmacology.

[57]  R. Donahue,et al.  A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. , 1999, Clinical therapeutics.

[58]  A. Ravindran,et al.  Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. , 1999, The Journal of clinical psychiatry.

[59]  J. Amsterdam,et al.  A Double-Blind Study of Paroxetine, Fluoxetine, and Placebo an Outpatients with Major Depression , 1998 .

[60]  F. Reimherr,et al.  A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients. , 1998, Clinical therapeutics.

[61]  L. Fabre,et al.  A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. , 1998, The Journal of clinical psychiatry.

[62]  David Healy,et al.  The Antidepressant Era , 1998 .

[63]  ArifUllah Khan,et al.  The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group. , 1998, Journal of clinical psychopharmacology.

[64]  J. Macher,et al.  Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations , 1998 .

[65]  S. Stahl,et al.  A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. , 1997, The Journal of clinical psychiatry.

[66]  M. Thase.  Efficacy and Tolerability of Once-Daily Venlafaxine Extended Release (XR) in Outpatients With Major Depression , 1997 .

[67]  L. Cunningham.  Once-Daily Venlafaxine Extended Release (XR) and Venlafaxine Immediate Release (IR) in Outpatients with Major Depression , 1997, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[68]  Y. Lecrubier,et al.  Efficacy of venlafaxine in depressive illness in general practice , 1997, Acta psychiatrica Scandinavica.

[69]  J. Claghorn,et al.  Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. , 1996, Journal of clinical psychopharmacology.

[70]  D. Sackett,et al.  Evidence based medicine: what it is and what it isn't , 1996, BMJ.

[71]  J. Mendels,et al.  Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo , 1995, Biological Psychiatry.

[72]  Bremner Jd.  A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. , 1995 .

[73]  J. Guelfi,et al.  Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. , 1995, The Journal of clinical psychiatry.

[74]  T. Baghai,et al.  Treatment of depressive outpatients with lorazepam, alprazolam, amytriptyline and placebo , 1995, Psychopharmacology.

[75]  M. C. Khan,et al.  A randomised, double‐blind, placebo‐controlled, 5‐weeks' study of org 3770 (mirtazapine) in major depression , 1995 .

[76]  J. Claghorn,et al.  A double-blind placebo-controlled study of Org 3770 in depressed outpatients. , 1995, Journal of affective disorders.

[77]  L. Mynors-Wallis,et al.  Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care , 1995, BMJ.

[78]  D. Altman,et al.  Statistic Notes: Regression towards the mean , 1994, BMJ.

[79]  E. Leinonen,et al.  Double-blind study of mirtazapine and placebo in hospitalized patients with major depression , 1994, European Neuropsychopharmacology.

[80]  A. Ontiveros,et al.  A double-blind comparison of nefazodone, imipramine, and placebo in major depression. , 1994, The Journal of clinical psychiatry.

[81]  C. Clary,et al.  Nefazodone and Imipramine in Major Depression: A Placebo-Controlled Trial , 1994, British Journal of Psychiatry.

[82]  B. Diamond,et al.  A comparison of venlafaxine, trazodone, and placebo in major depression. , 1994, Journal of clinical psychopharmacology.

[83]  J. Feighner,et al.  Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. , 1994, The Journal of clinical psychiatry.

[84]  T. Silverstone.  A multicentre comparative trial of moclobemide, imipramine and placebo in major depressive disorder , 1994, International clinical psychopharmacology.

[85]  G. Dunbar,et al.  A study comparing paroxetine placebo and imipramine in depressed patients. , 1993, Journal of affective disorders.

[86]  Feighner Jp.  A double-blind comparison of paroxetine, imipramine and placebo in depressed outpatients. , 1992 .

[87]  G. Dunbar,et al.  Paroxetine versus placebo: a double-blind comparison in depressed patients. , 1992, The Journal of clinical psychiatry.

[88]  A. Kiev.  A double-blind, placebo-controlled study of paroxetine in depressed outpatients. , 1992, The Journal of clinical psychiatry.

[89]  J. Amsterdam,et al.  The efficacy and safety of paroxetine compared with placebo in outpatients with major depression. , 1992, The Journal of clinical psychiatry.

[90]  L. Fabre.  A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. , 1992, The Journal of clinical psychiatry.

[91]  A. Schatzberg,et al.  Serotonin activity in psychotic (delusional) major depression. , 1992, The Journal of clinical psychiatry.

[92]  D. Sheehan,et al.  A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression , 1990, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[93]  T M Itil,et al.  Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. , 1990, The Journal of clinical psychiatry.

[94]  R. Baldessarini,et al.  Tyrosine for depression: a double-blind trial. , 1990, Journal of affective disorders.

[95]  J. Feighner,et al.  A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. , 1990, The Journal of clinical psychiatry.

[96]  D. Klein,et al.  Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression. , 1989, Archives of general psychiatry.

[97]  J. Feighner,et al.  A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression. , 1989, International clinical psychopharmacology.

[98]  J. K. Larsen,et al.  Moclobemide and clomipramine in reactive depression , 1989, Acta psychiatrica Scandinavica.

[99]  S. Miller,et al.  A double‐blind comparison of paroxetine and placebo in the treatment of depressed patients in a psychiatric outpatient clinic , 1989, Acta psychiatrica Scandinavica. Supplementum.

[100]  J. Feighner,et al.  A double-blind comparison of fluoxetine, imipramine and placebo in outpatients with major depression. , 1989, International clinical psychopharmacology.

[101]  E. Paykel,et al.  Double-blind placebo-controlled trial of amitriptyline among depressed patients in general practice. , 1988, The Journal of the Royal College of General Practitioners.

[102]  J. Amsterdam,et al.  Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression. , 1987, Archives of general psychiatry.

[103]  J. Mendels,et al.  Comparative efficacy of alprazolam, imipramine, and placebo administered once a day in treating depressed patients. , 1986, The Journal of clinical psychiatry.

[104]  J. Cohn,et al.  A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. , 1985, The Journal of clinical psychiatry.

[105]  J. Feighner,et al.  Alprazolam, amitriptyline, doxepin, and placebo in the treatment of depression. , 1985, Archives of general psychiatry.

[106]  B. Huitfeldt,et al.  A double-blind evaluation of zimelidine in comparison to placebo and amitmptyline in patients with major depressive disorder , 1983, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[107]  L. Fabre,et al.  Comparison of alprazolam, imipramine, and placebo in the treatment of depression. , 1983, JAMA.

[108]  R. Shrivastava,et al.  A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression. , 1983, British journal of clinical pharmacology.

[109]  W. E. Fann,et al.  Bupropion in depression: a tri-center placebo-controlled study. , 1983, The Journal of clinical psychiatry.

[110]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[111]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[112]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[113]  R. Baldessarini.  Chemotherapy in psychiatry , 2013 .

[114]  R. Baldessarini,et al.  Efficacy of Antimanic Treatments: Meta-analysis of Randomized, Controlled Trials , 2011, Neuropsychopharmacology.

[115]  S. K. Padmanabhan,et al.  Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. , 2009, Clinical therapeutics.

[116]  B. Birmaher,et al.  Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. , 2009, The American journal of psychiatry.

[117]  J. Ioannidis,et al.  Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? , 2008, Philosophy, ethics, and humanities in medicine : PEHM.

[118]  A. Schatzberg,et al.  Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. , 2005, Journal of psychiatric research.

[119]  J. McClure,et al.  A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study , 2005, Psychopharmacology.

[120]  G. Simpson,et al.  Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial , 2004, Psychopharmacology.

[121]  Dwight L. Evans,et al.  Comparison of pramipexole, fluoxetine, and placebo in patients with major depression , 2000, Depression and anxiety.

[122]  L. Fabre,et al.  Double‐blind comparison of citalopram and placebo in depressed outpatients with melancholia , 1999, Depression and anxiety.

[123]  J. Massana.  Reboxetine versus fluoxetine: an overview of efficacy and tolerability. , 1998, The Journal of clinical psychiatry.

[124]  A. Takahashi.  Rating scale for depression , 1998 .

[125]  J. Ieni,et al.  Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. , 1996, The Journal of clinical psychiatry.

[126]  J. Mendlewicz,et al.  A double-blind comparison of tianeptine, imipramine and placebo in the treatment of major depressive episodes , 1996, European Psychiatry.

[127]  Feiger Ad.  A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. , 1996, Psychopharmacology bulletin.

[128]  J. Cohn,et al.  A double‐blind, placebo‐controlled study comparing mianserin and amitriptyline in moderately depressed outpatients , 1994, International clinical psychopharmacology.

[129]  Doogan Dp,et al.  A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice. , 1994 .

[130]  E. Warga,et al.  A controlled study of mianserin in moderately to severely depressed outpatients. , 1991, Psychopharmacology bulletin.

[131]  ArifUllah Khan,et al.  Venlafaxine in depressed outpatients. , 1991, Psychopharmacology bulletin.

[132]  Ward T. Smith,et al.  Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. , 1990, Psychopharmacology bulletin.

[133]  J. Wernicke,et al.  Low-dose fluoxetine therapy for depression. , 1988, Psychopharmacology bulletin.

[134]  R. Zerbe,et al.  Fixed-dose fluoxetine therapy for depression. , 1987, Psychopharmacology bulletin.